Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $-83M | $-117M | $-79M | -228.0% | 181.5% | 40.3% |
| 2024 | $2M | $-88M | $-84M | $-78M | -52.1% | - | 3.0% |
| 2023 | $0M | $-81M | $-81M | $-75M | -47.8% | - | 39.9% |
| 2022 | $0M | $-56M | $-58M | $-59M | 58.6% | - | - |
| 2021 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 6.39 |
| Operating Revenue | 6.39 |
| Operating Expense | 93.73 |
| Research And Development | 65.58 |
| Selling General And Administration | 28.16 |
| Total Expenses | 93.73 |
| Operating Income | -87.34 |
| Total Operating Income As Reported | -121.86 |
| EBITDA | -83.06 |
| Normalized EBITDA | -48.55 |
| EBIT | -87.34 |
| Interest Income | - |
| Interest Expense | - |
| Net Interest Income | - |
| Other Non Operating Income Expenses | 5.23 |
| Other Income Expense | -29.28 |
| Interest Income Non Operating | - |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | - |
| Pretax Income | -116.62 |
| Tax Provision | 0.64 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -7.25 |
| Net Income Continuous Operations | -117.26 |
| Net Income From Continuing And Discontinued Operation | -117.26 |
| Net Income From Continuing Operation Net Minority Interest | -117.26 |
| Net Income | -117.26 |
| Net Income Common Stockholders | -117.26 |
| Net Income Including Noncontrolling Interests | -117.26 |
| Normalized Income | -89.99 |
| Diluted NI Availto Com Stockholders | -117.26 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 4.28 |
| Total Unusual Items | -34.51 |
| Total Unusual Items Excluding Goodwill | -34.51 |
| Special Income Charges | -34.51 |
| Impairment Of Capital Assets | 30.89 |
| Restructuring And Mergern Acquisition | 3.63 |
| General And Administrative Expense | 28.16 |
| Other Gand A | 13.76 |
| Salaries And Wages | 14.39 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Korro Bio, Inc.this co. | KRRO | $161M | -1.38 | 3.13 | -228.0% | -2.20 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Journey Medical Corporation | DERM | $171M | -14.98 | 5.38 | -35.9% | -51.87 |
| Inogen, Inc. | INGN | $171M | -7.51 | 0.89 | -11.8% | -8.86 |
| ADC Therapeutics SA | ADCT | $168M | -1.18 |
| - |
| - |
| - |
| -0.90 |
| 76.7% |
| -0.27 |
| Protalix BioTherapeutics, Inc. | PLX | $162M | - | 3.36 | -13.7% | - |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Nano-X Imaging Ltd. | NNOX | $144M | -1.92 | 1.03 | -53.7% | -2.10 |
| Health Catalyst, Inc. | HCAT | $143M | -0.81 | 0.58 | -72.4% | -2.57 |
| Peer Median | - | -1.80 | 0.96 | -36.1% | -2.34 | |